271 related articles for article (PubMed ID: 22412061)
1. Cost-effectiveness and population outcomes of general population screening for hepatitis C.
Coffin PO; Scott JD; Golden MR; Sullivan SD
Clin Infect Dis; 2012 May; 54(9):1259-71. PubMed ID: 22412061
[TBL] [Abstract][Full Text] [Related]
2. Healthcare value of implementing hepatitis C screening in the adult general population in Spain.
Buti M; Domínguez-Hernández R; Casado MÁ; Sabater E; Esteban R
PLoS One; 2018; 13(11):e0208036. PubMed ID: 30485377
[TBL] [Abstract][Full Text] [Related]
3. Economic model of a birth cohort screening program for hepatitis C virus.
McGarry LJ; Pawar VS; Panchmatia HR; Rubin JL; Davis GL; Younossi ZM; Capretta JC; O'Grady MJ; Weinstein MC
Hepatology; 2012 May; 55(5):1344-55. PubMed ID: 22135116
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
Chahal HS; Marseille EA; Tice JA; Pearson SD; Ollendorf DA; Fox RK; Kahn JG
JAMA Intern Med; 2016 Jan; 176(1):65-73. PubMed ID: 26595724
[TBL] [Abstract][Full Text] [Related]
6. Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective?
Urbanus AT; van Keep M; Matser AA; Rozenbaum MH; Weegink CJ; van den Hoek A; Prins M; Postma MJ
PLoS One; 2013; 8(8):e70319. PubMed ID: 23950920
[TBL] [Abstract][Full Text] [Related]
7. Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based Hepatitis C Testing in the United States.
Barocas JA; Tasillo A; Eftekhari Yazdi G; Wang J; Vellozzi C; Hariri S; Isenhour C; Randall L; Ward JW; Mermin J; Salomon JA; Linas BP
Clin Infect Dis; 2018 Aug; 67(4):549-556. PubMed ID: 29420742
[TBL] [Abstract][Full Text] [Related]
8. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
10. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.
Liu S; Cipriano LE; Holodniy M; Owens DK; Goldhaber-Fiebert JD
Ann Intern Med; 2012 Feb; 156(4):279-90. PubMed ID: 22351713
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States.
Tatar M; Keeshin SW; Mailliard M; Wilson FA
JAMA Netw Open; 2020 Sep; 3(9):e2015756. PubMed ID: 32880650
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.
Rein DB; Smith BD; Wittenborn JS; Lesesne SB; Wagner LD; Roblin DW; Patel N; Ward JW; Weinbaum CM
Ann Intern Med; 2012 Feb; 156(4):263-70. PubMed ID: 22056542
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.
Blázquez-Pérez A; San Miguel R; Mar J
Pharmacoeconomics; 2013 Oct; 31(10):919-31. PubMed ID: 24000086
[TBL] [Abstract][Full Text] [Related]
16. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of One-Time Birth Cohort Screening for Hepatitis C as Part of the National Health Service Health Check Program in England.
Williams J; Miners A; Harris R; Mandal S; Simmons R; Ireland G; Hickman M; Gore C; Vickerman P
Value Health; 2019 Nov; 22(11):1248-1256. PubMed ID: 31708061
[TBL] [Abstract][Full Text] [Related]
18. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
19. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis.
Arguedas MR; Chen VK; Eloubeidi MA; Fallon MB
Am J Gastroenterol; 2003 Mar; 98(3):679-90. PubMed ID: 12650806
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
Saab S; Virabhak S; Parisé H; Johnson S; Wang A; Misurski D; Gonzalez YS; Juday T
Adv Ther; 2016 Aug; 33(8):1316-30. PubMed ID: 27342742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
